Seroquel- Agitation associated with Dementia
Study identifier:5077US/0046
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A multicenter, double-blind, randomized, comparison of the efficacy and safety of Quetiapine Fumarate (SEROQUEL) and placebo in the treatment of agitation associated with dementia.
Medical condition
Alzheimer's disease
Phase
Phase 3
Healthy volunteers
No
Study drug
Quetiapine Fumarate, Placebo
Sex
All
Actual Enrollment
333
Study type
Interventional
Age
55 Years +
Date
Study Start Date: 01 Sept 2002
Primary Completion Date: 01 Nov 2003
Study Completion Date: 01 Nov 2003
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 1st fixed dose | - |
| Experimental: 2 2nd fixed dose | - |
| Sham Comparator: 3 Placebo | - |
